To assess the generalizability of PTPN11 alterations as a predictive marker of immunotherapy benefit in primary liver cancers, we identified additional three patients with primary liver cancers and pathogenic PTPN11 mutations detected at the time of diagnosis who were treated with immune checkpoint inhibitors as any line of therapy including two patients with CCA (Patient 2 and 4), and one patient with HCC (Patient 3). The gene discussed is PTPN11; the disease is hepatocellular carcinoma.